SecBot SecBot
144 ·Filed May 7, 2026

RAPP

Rapport Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago SEC0001974078-26-000168
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

Third Rock Ventures continues to distribute shares, likely for fund-level liquidity. The stock may face modest selling pressure near the proposed sale price. Watch for additional Form 144 or Form 4 filings to gauge the pace of distribution.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
RAPP ▲ +10.94% at T+60d
NEUTRAL call ✓ call won +10.94% · α vs SPY +6.10% · entry $38.04 → $42.20
Entry anchored
May 7, 2026
via day open
T+1d
+1.03%
call +1.03% · α +0.79%
$38.43
settled 6mo ago
T+5d
-0.24%
call -0.24% · α -1.70%
$37.95
settled 6mo ago
T+20d
-5.10%
call -5.10% · α -5.12%
$36.10
settled 5mo ago
T+60d
+10.94%
call +10.94% · α +6.10%
$42.20
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Third Rock Ventures V, L.P., a 10% stockholder, filed a Form 144 indicating intent to sell 271,495 shares of Rapport Therapeutics common stock, valued at approximately $10.9 million. This follows a prior sizable sale of 426,005 shares (~$17.2M) on April 17, 2026, signaling ongoing distribution by a major venture capital backer.

Key Facts

  • Third Rock Ventures V, L.P. proposes to sell 271,495 shares.
  • Estimated aggregate market value of proposed sale: $10,892,705.19.
  • Shares acquired on 02/21/2023 via original issuance from the issuer.
  • Prior sale of 426,005 shares (~$17.2M) on 04/17/2026 by the same entity.
  • Recent insider activity (30d): 6 sells totaling $18.7M (prior to this filing).

Financial Impact

Proposed sale of ~$10.9M (0.6% of $1.8B market cap) adds to recent insider selling of $18.7M over the past 30 days.

dilution (secondary sales)supply overhang

Risk Factors

  • Continued insider selling could pressure share price.
  • VC distributions often persist over multiple weeks/months.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001974078-26-000168
Document: 0001974078-26-000168-index.html0001974078-26-000168
Document: 0001974078-26-000168.txt0001974078-26-000168
22 reports for RAPP
Performance horizon
67% Hit rate @ T+5 4 of 6 directional calls Went positive at some point 6 of 8 best @ T+60▲ +24.87%Mar 10, 2026
Filters
Rows
Reports for RAPP — sortable, filterable
TypeNow
Oct 23, 2026
2d ago
Insider Cluster
BULLISH ★ 5/10
$26.00awaiting T+5—$25.93 (−0.27%)
Oct 22, 2026
4d ago
Insider Cluster
BULLISH ★ 5/10
$27.33awaiting T+5—$25.93 (−5.12%)
Oct 21, 2026
4d ago
Insider Buy
BULLISH ★ 4/10
$26.53awaiting T+5—$25.93 (−2.26%)
Oct 20, 2026
6d ago
8-K
BULLISH ★ 7/10
$29.37awaiting T+5—$25.93 (−11.71%)
Oct 6, 2026
19d ago
144
BEARISH ★ 5/10
$30.86 $28.33▲ +8.20%▲ +7.22%$25.93 (+15.98%)
Oct 1, 2026
24d ago
Insider Cluster
NEUTRAL ★ 3/10
$32.17 $30.65▼ −4.72%▼ −5.89%$25.93 (−19.40%)
Aug 26, 2026
8w ago
Insider Cluster
NEUTRAL ★ 3/10
$50.83 $47.65▼ −6.26%▼ −6.52%$25.93 (−48.99%)
Aug 5, 2026
11w ago
8-K
MIXED ★ 5/10
$42.44 $47.73▲ +12.46%▲ +12.11%$25.93 (−38.90%)
Jul 1, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$38.97 $41.75▲ +7.13%▲ +5.77%$25.93 (−33.46%)
Jun 30, 2026
16w ago
144
NEUTRAL ★ 2/10
$39.39 $39.72▲ +0.84%▲ +0.58%$25.93 (−34.17%)
Showing 10 of 22

US Market Status

Market Closed — Opens in 2h 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers